About Acura Pharmaceuticals (OTCMKTS:ACUR)
Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.
Industry, Sector and Symbol
Industry Drug Delivery
SymbolOTCMKTS:ACURPrevious Symbol: NASDAQ:ACUR
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$4.46 million
Price / Sales1.96
Price / CashN/A
Book Value$0.08 per share
Price / Book5.26
Return on Equity-231.18%
Return on Assets-31.56%
Frequently Asked Questions for Acura Pharmaceuticals (OTCMKTS:ACUR)
What is Acura Pharmaceuticals' stock symbol?
Acura Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ACUR."
How were Acura Pharmaceuticals' earnings last quarter?
Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) released its quarterly earnings results on Monday, November, 13th. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter. The specialty pharmaceutical company earned $0.08 million during the quarter. Acura Pharmaceuticals had a negative net margin of 36.20% and a negative return on equity of 231.18%. View Acura Pharmaceuticals' Earnings History.
Who are some of Acura Pharmaceuticals' key competitors?
Some companies that are related to Acura Pharmaceuticals include Ritter Pharmaceuticals (RTTR), Repros Therapeutics (RPRX), Innovus Pharmaceuticals (INNV), Neuralstem (CUR), Heat Biologics (HTBX), Capnia (SLNO), Critical Outcome Technologies (COTQF), Senesco Technologies (SVON), Immune Pharmaceuticals (IMNP), Novogen Limited (NVGN), OpGen (OPGN), Galena Biopharma (GALE), Transgenomic (PRPO), Dynatronics Corporation (DYNT), Cytori Therapeutics (CYTX), Jaguar Animal Health (JAGX), Alliqua BioMedical (ALQA) and Senestech (SNES).
Who are Acura Pharmaceuticals' key executives?
Acura Pharmaceuticals' management team includes the folowing people:
- Robert B. Jones, President, Chief Executive Officer, Director (Age 58)
- Peter A. Clemens, Chief Financial Officer, Senior Vice President, Secretary (Age 64)
- Robert A. Seiser CPA, Vice President, Corporate Controller and Treasurer (Age 53)
- J. Bradley Rivet, Vice President - Marketing (Age 63)
- Albert W. Brzeczko Ph.D., Vice President -Technical Affairs (Age 60)
- James F. Emigh, Vice President - Corporate Development (Age 61)
- George K. Ross, Independent Director (Age 75)
- William G. Skelly, Independent Director (Age 66)
- Immanuel Thangaraj, Independent Director (Age 45)
- Bruce F. Wesson, Independent Director (Age 74)
How do I buy Acura Pharmaceuticals stock?
Shares of Acura Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acura Pharmaceuticals' stock price today?
One share of Acura Pharmaceuticals stock can currently be purchased for approximately $0.42.
How big of a company is Acura Pharmaceuticals?
Acura Pharmaceuticals has a market capitalization of $8.77 million and generates $4.46 million in revenue each year. The specialty pharmaceutical company earns $-7,380,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Acura Pharmaceuticals employs 15 workers across the globe.
How can I contact Acura Pharmaceuticals?
Acura Pharmaceuticals' mailing address is 616 N. NORTH COURT SUITE 120, PALATINE IL, 60067. The specialty pharmaceutical company can be reached via phone at 847-705-7709 or via email at [email protected]
MarketBeat Community Rating for Acura Pharmaceuticals (ACUR)MarketBeat's community ratings are surveys of what our community members think about Acura Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Acura Pharmaceuticals (OTCMKTS:ACUR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Acura Pharmaceuticals (OTCMKTS:ACUR)
Analysts' Ratings History for Acura Pharmaceuticals (OTCMKTS:ACUR)
(Data available from 11/23/2015 forward)
|10/21/2016||FBR & Co||Reiterated Rating||Outperform||$10.00|
|10/18/2016||Roth Capital||Set Price Target||Buy||$6.00|
Earnings History and Estimates Chart for Acura Pharmaceuticals (OTCMKTS:ACUR)
Earnings History by Quarter for Acura Pharmaceuticals (OTCMKTS ACUR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/13/2017||Q3 2017||($0.12)||$0.08 million||View||N/A|
|8/14/2017||Q2 2017||($0.11)||($0.18)||$0.09 million||View||N/A|
|5/12/2017||Q1 2017||($0.11)||$0.03||$0.34 million||$2.72 million||View||N/A|
|11/14/2016||Q3||($0.27)||($0.19)||$0.23 million||$0.22 million||View||N/A|
|8/8/2016||Q2||($0.28)||($0.28)||$0.19 million||$0.26 million||View||N/A|
|5/2/2016||Q116||($0.26)||($0.28)||$0.15 million||$0.22 million||View||N/A|
|2/29/2016||Q315||($0.03)||($0.08)||$2.70 million||$2.68 million||View||Listen|
|8/3/2015||Q215||($0.02)||($0.05)||$2.90 million||$0.34 million||View||N/A|
|5/4/2015||Q115||$0.07||$0.03||$7.60 million||$5.40 million||View||N/A|
|3/2/2015||Q414||($0.09)||($0.06)||$0.05 million||$0.53 million||View||N/A|
|11/3/2014||Q3 2014||($0.08)||($0.06)||$0.05 million||$0.15 million||View||N/A|
Earnings Estimates for Acura Pharmaceuticals (OTCMKTS:ACUR)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Acura Pharmaceuticals (OTCMKTS:ACUR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Acura Pharmaceuticals (OTCMKTS ACUR)
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 9.41%
Insider Trades by Quarter for Acura Pharmaceuticals (OTCMKTS ACUR)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/29/2017||Albert W Brzeczko||VP||Buy||10,800||$0.47||$5,076.00|| |
|6/17/2015||Claudius Llc||Major Shareholder||Sell||104,823||$1.08||$113,208.84|| |
|1/12/2015||Claudius Llc||Major Shareholder||Sell||171,000||$0.62||$106,020.00|| |
|5/22/2014||William G Skelly||Director||Sell||4,600||$1.23||$5,658.00|| |
|5/20/2014||William G Skelly||Director||Sell||5,000||$1.21||$6,050.00|| |
|5/19/2014||Albert W Brzeczko||VP||Buy||2,000||$1.20||$2,400.00|| |
|5/16/2014||Bruce F Wesson||Director||Buy||80,000||$1.13||$90,400.00|| |
|5/16/2014||James F Emigh||VP||Buy||15,000||$1.21||$18,150.00|| |
|5/16/2014||Peter A Clemens||CFO||Buy||3,000||$1.21||$3,630.00|| |
|5/14/2014||William G Skelly||Director||Sell||2,900||$1.21||$3,509.00|| |
|5/12/2014||William G Skelly||Director||Sell||5,000||$1.25||$6,250.00|| |
|5/8/2014||William G Skelly||Director||Sell||2,500||$1.30||$3,250.00|| |
|3/3/2014||Claudius Llc||Major Shareholder||Sell||2,500||$2.00||$5,000.00|| |
|2/28/2014||Claudius Llc||Major Shareholder||Sell||351,260||$2.02||$709,545.20|| |
|2/24/2014||Claudius Llc||Major Shareholder||Sell||44,019||$1.97||$86,717.43|| |
|11/25/2013||Albert W Brzeczko||VP||Buy||1,215||$1.70||$2,065.50|| |
|10/10/2013||Claudius Llc||Major Shareholder||Sell||4,200||$2.05||$8,610.00|| |
|8/27/2013||William G Skelly||Director||Sell||2,000||$1.55||$3,100.00|| |
|7/15/2013||Care Capital Ii Llc||Major Shareholder||Sell||31,610||$2.04||$64,484.40|| |
|7/3/2013||Care Capital Ii Llc||Major Shareholder||Sell||14,200||$2.00||$28,400.00|| |
|7/2/2013||Claudius Llc||Major Shareholder||Sell||200,000||$2.15||$430,000.00|| |
|6/27/2013||Care Capital Ii Llc||Major Shareholder||Sell||76,281||$2.01||$153,324.81|| |
|6/24/2013||Care Capital Ii Llc||Major Shareholder||Sell||83,000||$2.03||$168,490.00|| |
|6/19/2013||Care Capital Ii Llc||Major Shareholder||Sell||114,000||$2.12||$241,680.00|| |
|6/17/2013||Claudius Llc||Major Shareholder||Sell||20,446||$2.15||$43,958.90|| |
|6/14/2013||Care Capital Ii Llc||Major Shareholder||Sell||90,000||$2.16||$194,400.00|| |
|6/11/2013||Care Capital Ii Llc||Major Shareholder||Sell||102,000||$2.19||$223,380.00|| |
|6/10/2013||Claudius Llc||Major Shareholder||Sell||21,496||$2.20||$47,291.20|| |
|6/6/2013||Claudius Llc||Major Shareholder||Sell||39,453||$2.19||$86,402.07|| |
|6/3/2013||Care Capital Ii Llc||Major Shareholder||Sell||148,000||$2.24||$331,520.00|| |
|5/31/2013||Claudius Llc||Major Shareholder||Sell||31,559||$2.25||$71,007.75|| |
|5/29/2013||Care Capital Ii Llc||Major Shareholder||Sell||108,701||$2.33||$253,273.33|| |
|5/28/2013||William G Skelly||Director||Sell||2,000||$2.40||$4,800.00|| |
|5/23/2013||Care Capital Ii Llc||Major Shareholder||Sell||252,000||$2.31||$582,120.00|| |
|5/22/2013||William G Skelly||Director||Sell||4,000||$2.33||$9,320.00|| |
|5/21/2013||Claudius Llc||Major Shareholder||Sell||47,410||$2.30||$109,043.00|| |
|5/20/2013||Care Capital Ii Llc||Major Shareholder||Sell||510,000||$2.36||$1,203,600.00|| |
|5/16/2013||Care Capital Ii Llc||Major Shareholder||Sell||662,000||$2.38||$1,575,560.00|| |
|5/16/2013||William G Skelly||Director||Sell||3,000||$2.25||$6,750.00|| |
|5/15/2013||Claudius Llc||Major Shareholder||Sell||183,434||$2.33||$427,401.22|| |
|5/13/2013||Care Capital Ii Llc||Major Shareholder||Sell||259,000||$2.19||$567,210.00|| |
|5/9/2013||William G Skelly||Director||Sell||3,000||$2.20||$6,600.00|| |
|4/11/2013||Claudius Llc||Major Shareholder||Sell||121,454||$2.23||$270,842.42|| |
|3/26/2013||Care Capital Ii Llc||Major Shareholder||Sell||39,554||$2.17||$85,832.18|| |
Latest Headlines for Acura Pharmaceuticals (OTCMKTS ACUR)
Acura Pharmaceuticals (OTCMKTS ACUR) Chart for Thursday, November, 23, 2017